7a allg. zu Impfungen/ vaccinations
» MS und Impfung
Letzte Änderung: 07.04.2023 um 17:47 Uhr
Weiterführende Links zum Artikel
★SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
(Hinzugefügt: 26.10.2022 um 14:27 Uhr)
★Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
(Hinzugefügt: 13.05.2022 um 07:02 Uhr)
★Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis
(Hinzugefügt: 26.09.2021 um 08:33 Uhr)
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
(Hinzugefügt: 13.05.2022 um 07:18 Uhr)
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab
(Hinzugefügt: 11.03.2022 um 11:19 Uhr)
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
(Hinzugefügt: 23.02.2022 um 11:43 Uhr)
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
(Hinzugefügt: 17.02.2022 um 06:40 Uhr)
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
(Hinzugefügt: 10.01.2022 um 13:10 Uhr)
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
(Hinzugefügt: 23.12.2021 um 20:03 Uhr)
STELLUNGNAHME ZU COVID-19-IMPFSTOFFEN UND AUSLÖSUNG VON KRANKHEITSSCHÜBEN/-AKTIVITÄT BEI MULTIPLE SKLEROSE - ERKRANKTEN
(Hinzugefügt: 18.10.2021 um 11:09 Uhr)
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
(Hinzugefügt: 26.09.2021 um 08:33 Uhr)
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
(Hinzugefügt: 24.08.2021 um 16:18 Uhr)
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
(Hinzugefügt: 04.07.2021 um 06:11 Uhr)